Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Equity Income of -$470000.0 in Q1 2024, up 88.81% quarter-over-quarter from -$4.2 million in Q4 2023.
Crinetics Pharmaceuticals (CRNX) Equity Income (2022 - 2024) Analysis & Trends
Crinetics Pharmaceuticals' Equity Income history runs 3 years deep, the most recent figure standing at -$470000.0 for Q1 2024.
- In Q1 2024, Equity Income changed N/A year-over-year to -$470000.0; the TTM figure through Dec 2024 stood at -$470000.0 (up 90.96% YoY), while the FY2024 annual figure was -$470000.0, up 90.96% from the prior year.
- Equity Income was -$470000.0 for Q1 2024 at Crinetics Pharmaceuticals, up from -$4.2 million in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$470000.0 in Q1 2024 to a low of -$4.2 million in Q4 2023.
- Historically, Equity Income has averaged -$1.7 million across 3 years, with a median of -$1.0 million in 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -470,000.00 |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | -997,000.00 |
| Mar 31, 2022 | -1.01 Mn |